NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Copyright Public domain Remove constraint Copyright: Public domain Publication Year 2000 to 2023 Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2023">2023</span>

Search Results

5. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

8. ACF cannot ensure that all child victims of abuse and neglect have court representation

10. ACOs' strategies for transitioning to value-based care: lessons from the Medicare shared savings program

14. Abuse and neglect: CMS should strengthen reporting requirements to better protect individuals receiving hospice care : report to the Honorable Charles E. Grassley, United States Senate

15. Accelerating adoption of assistive technology to reduce physical strain among family caregivers of the chronically disabled elderly living at home

17. Access and use of electronic health information by individuals with cancer: 2017-2018

19. Access to preventive services without cost-sharing: evidence from the Affordable Care Act

20. The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

22. Acne vulgaris: establishing effectiveness of drugs intended for treatment

25. Adaptive designs for clinical trials of drugs and biologics

29. Addressing social determinants of health: examples of successful evidence-based strategies and current federal efforts

30. Addressing teen pregnancy risks for youth living in out-of-home care: implementing POWER through choices 2010 : implementation report

33. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

34. The Admissibility of Scientific Evidence in Court

35. Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees

36. Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report

38. Advancement of emerging technology applications for pharmaceutical innovation and modernization

40. Advancing primary prevention in human services. Key considerations for administrators and practitioners

41. Advancing primary prevention in human services. Key considerations for policy designers and funding partners

42. Advancing primary prevention in human services. Opportunities for people with lived experience

43. Advancing primary prevention in human services: convening findings

44. Advancing research on intersections of child welfare and Medicaid using linked data from the CCOULD project

46. Adverse events in long-term-care hospitals: national incidence among Medicare beneficiaries

49. The Affordable Care Act and African Americans

50. The Affordable Care Act and Asian Americans and Pacific Islanders

51. The Affordable Care Act and Latinos

52. The Affordable Care Act and adolescents

53. The Affordable Care Act and women

54. Affordable Care Act has led to historic, widespread increase in health insurance coverage

55. Affordable Care Act: IRS should mitigate limitations of data to be used for the age and gender adjustment for the tax on high-cost health plans : report to Congressional committees

56. The Affordable Care Act: advancing the health of women and children

58. The aging services network: accomplishments and challenges in serving a growing elderly population

59. Air ambulance: data collection and transparency needed to enhance DOT oversight : report to the Committee on Transportation and Infrastructure, House of Representatives

61. Air travel and communicable diseases: status of research efforts and action still needed to develop federal preparedness plan : testimony before the Subcommittee on Space and Aeronautics, Committee on Science, Space, and Technology, House of Representatives

63. Allergic rhinitis: developing drug products for treatment

64. Alternative payment models and the slowdown in federal health care spending: testimony before the Committee on the Budget, United States Senate

66. Alternative procedures for the manufacture of cold-stored platelets intended for the treatment of active bleeding when conventional platelets are not available or their use is not practical: guidance for industry

68. An American Indian/Alaska Native suicide prevention hotline: literature review and discussion with experts

69. Amyotrophic lateral sclerosis: developing drugs for treatment

70. Analysis of 2017 premium changes and insurer participation in the Affordable Care Act's health insurance marketplaces

71. An analysis of private-sector prices for hospital admissions

73. Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV): final report

75. Animal use in research: NIH should strengthen oversight of projects it funds at foreign facilities : report to congressional requesters

79. Anthrax: developing drugs for prophylaxis of inhalational anthrax

80. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

81. Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

83. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

84. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

86. Antipsychotic medication prescribing in long-term care facilities increased in the early months of the COVID-19 pandemic

88. Appeal options available to mammography facilities concerning adverse accreditation decisions, suspension/revocation of certificates, or patient and physician notification orders: guidance for mammography facilities and Food and Drug Administration staff

92. Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff

94. Arthroscopy pump tubing sets intended for multiple patient use - Premarket Notification (510(k)) submissions: guidance for industry and Food and Drug Administration staff

95. Artificial intelligence in health care: benefits and challenges of machine learning technologies for medical diagnostics : report to congressional requesters

96. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

97. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment